Generali Asset Management SPA SGR Cuts Holdings in McKesson Corporation $MCK

Generali Asset Management SPA SGR trimmed its holdings in shares of McKesson Corporation (NYSE:MCK) by 11.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,723 shares of the company’s stock after selling 912 shares during the quarter. Generali Asset Management SPA SGR’s holdings in McKesson were worth $5,515,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Swedbank AB boosted its holdings in shares of McKesson by 42.2% during the 4th quarter. Swedbank AB now owns 886,283 shares of the company’s stock worth $727,009,000 after purchasing an additional 263,189 shares during the last quarter. SurgoCap Partners LP grew its position in shares of McKesson by 68.7% in the third quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock valued at $349,390,000 after purchasing an additional 184,106 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in shares of McKesson by 73.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 432,578 shares of the company’s stock valued at $354,839,000 after purchasing an additional 183,590 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in McKesson during the third quarter worth approximately $135,352,000. Finally, Danske Bank A S purchased a new position in McKesson during the third quarter worth approximately $127,487,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Stock Performance

Shares of MCK stock opened at $734.93 on Friday. McKesson Corporation has a fifty-two week low of $637.00 and a fifty-two week high of $999.00. The company has a 50 day moving average price of $883.74 and a 200 day moving average price of $859.93. The stock has a market capitalization of $90.02 billion, a P/E ratio of 19.10, a price-to-earnings-growth ratio of 1.09 and a beta of 0.35.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.56 by $0.13. McKesson had a negative return on equity of 378.75% and a net margin of 1.18%.The company had revenue of $96.30 billion for the quarter, compared to analyst estimates of $101.35 billion. During the same quarter last year, the company earned $10.12 EPS. McKesson’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, research analysts forecast that McKesson Corporation will post 44.24 EPS for the current fiscal year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s payout ratio is 8.53%.

Insider Buying and Selling

In related news, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares of the company’s stock, valued at $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michele Lau sold 2,725 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the transaction, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. The trade was a 45.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,264 shares of company stock worth $3,205,315 over the last 90 days. 0.08% of the stock is owned by insiders.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat quarterly adjusted EPS estimates, reporting $11.69 per share versus $11.56 expected, and cited strength in oncology, specialty distribution, and biopharma services. Reuters article
• Positive Sentiment: The company guided fiscal 2027 EPS to $43.80-$44.60, which is roughly in line with expectations and suggests continued earnings growth. McKesson also reaffirmed its long-term financial targets. Yahoo Finance article
• Positive Sentiment: JPMorgan lowered its price target to $1,015 from $1,107 but kept an overweight rating, implying meaningful upside from the current share price. Benzinga article
• Positive Sentiment: William Blair reiterated a Buy rating, saying McKesson’s durable earnings power and fiscal 2027 growth outlook outweigh near-term revenue softness. TipRanks article
• Neutral Sentiment: McKesson advanced plans for its $13 billion medical-surgical spinoff/separation, a strategic move that could unlock value over time but also adds execution risk. MSN article
• Negative Sentiment: Revenue came in below Wall Street forecasts at $96.3 billion versus $101.35 billion expected, reinforcing concerns about softer sales momentum despite improved margins. Yahoo Finance article
• Negative Sentiment: The stock has been trading lower as investors focus on the revenue shortfall and near-term softness in the medical-surgical business, even with strong earnings and guidance. Zacks article

Analyst Ratings Changes

Several brokerages have recently weighed in on MCK. Robert W. Baird set a $968.00 price target on shares of McKesson in a research report on Wednesday, January 14th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $875.00 target price on shares of McKesson in a report on Friday. UBS Group increased their price target on shares of McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Friday. Leerink Partners restated an “outperform” rating and set a $1,085.00 price target on shares of McKesson in a report on Thursday, March 5th. Finally, TD Cowen lifted their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and an average target price of $970.73.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.